Longevity: Marketing Hope

When it comes to slowing biological aging, the strongest human evidence still points to the basics over expensive “longevity center” procedures. There is a booming market built around the promise of living longer and staying biologically younger: Plasma exchange. Hyperbaric oxygen. IV nutrient infusions. Photobiomodulation. Peptide cocktails. NAD+ boosters. Senolytics.

The science behind some of these approaches is fascinating. But fascinating biology does not equal clinical benefit.

The real way to slow biological aging 

The best evidence is less exotic: exercise (resistance and cardio), a healthy plant-forward diet, maintaining a healthy weight and metabolic health, adequate sleep, healthy stress management, social connections, and other established lifestyle measures remain the foundation.

I am proof that lifestyle plus a few strategic supplements works.

At a chronologic age of 64, my TruDiagnostic biologic age is 46. My Dunedin pace of aging is 0.8 yrs for every chronologic year. And, I’ve had improved telomere length since starting Lifescape in 2003. All of this is evidence that small lifestyle changes, deployed consistently, have massive impact over decades.

What are the “biological clocks”?

Epigenetic clocks (such as TruDiagnostic) estimate biological aging from chemical methylation marks on DNA.

The newer clocks are beginning to predict health outcomes and mortality risk. But an important caveat often gets lost in longevity marketing: a positive change in an epigenetic clock does not prove someone will live longer, avoid dementia, or prevent chronic disease. However, over time, they can be helpful tools to assess whether your interventions are working for you.

In other words, these clocks are useful biomarkers — but they are not yet crystal balls. That distinction matters when evaluating expensive treatments marketed as “anti-aging.”

You cannot biohack around poor lifestyle choices

Lifestyle maintains the most consistent human longevity evidence.

A randomized trial known as the DAMA study followed 219 postmenopausal women for two years (Fiorito et al., Aging Cell, 2021). Participants assigned to a dietary intervention showed a significant slowing of the DNAmGrimAge clock, while increasing physical activity reduced certain epigenetic mutations associated with cancer pathways.

More recently, a large prospective study of 1,039 adults in the Young Finns Study found that healthier dietary patterns were associated with slower aging across GrimAge, PhenoAge and DunedinPACE (Autio et al., Journal of Nutrition, 2026). The relationship was particularly apparent among people with lower levels of physical activity.

A 2026 systematic review reached a similar overall conclusion: among interventions studied in humans, exercise, plant-rich diets and caloric restriction were among the approaches associated with improved epigenetic aging (Johnson & Sinclair, Frontiers in Genetics, 2026). Omega-3 fatty acids and multivitamin-mineral supplementation also showed signals of benefit, although the evidence is much less definitive than it is for lifestyle.

The message is remarkably straightforward: if you’re looking to improve your long-term health, don’t let cutting-edge interventions distract you from proven interventions backed by decades of human evidence.

What about expensive longevity-center treatments?

This is where the evidence becomes much thinner…

Plasma exchange: intriguing, but conflicting

Therapeutic plasma exchange (TPE), sometimes called plasmapheresis, is one of the more interesting examples because the human evidence points in opposite directions.

One 2025 randomized study in healthy adults found NO evidence of epigenetic rejuvenation from its plasmapheresis protocol (Borsky et al., Scientific Reports, 2025). In fact, several clocks — including GrimAge and DunedinPACE — moved in the direction of faster biological aging.

But another randomized, placebo-controlled study involving 42 adults over age 50 reported improvements across 15 epigenetic clocks with certain TPE protocols, particularly when TPE was performed every two weeks and paired with intravenous immunoglobulin (Fuentealba et al., Aging Cell, 2025).

So which study is right? We do not know yet.

The protocols were different, including differences in what was removed and what was given back. Baseline health and treatment schedules may also matter.

Conflicting trials are a reason for more research, not a reason to market a treatment as proven.

Hyperbaric oxygen: interesting signal, insufficient proof

Hyperbaric oxygen therapy (HBOT) has generated considerable excitement.

A 2020 prospective study gave 35 healthy adults age 64 and older 60 daily HBOT sessions (Hachmo et al., Aging, 2020). Researchers reported increases of more than 20% in telomere length in several immune-cell populations, along with reductions in some senescent immune cells.

That’s interesting.

But it was a small study without a control group, and it did not establish that HBOT slows the newer epigenetic clocks associated with biological aging.

It also doesn’t answer the question patients ultimately care about: Does this help people live healthier, longer lives?

At this point, the answer remains unknown.

IV therapies and photobiomodulation

IV nutrient infusions and photobiomodulation are widely promoted in the wellness and longevity marketplace.

The problem is not necessarily that they have been proven ineffective. It’s that there is very little high-quality human evidence showing that they improve the biological-aging endpoints being marketed to patients.

That distinction is important.

An intervention can be biologically plausible, relatively safe in some circumstances, or even helpful for a particular medical condition without being a proven anti-aging therapy.

IV treatment also isn’t risk-free. Potential complications include infection, phlebitis, blood clots, allergic reactions, and other line-related problems.

Peptides: promising science, scant human evidence

Gray market (unregulated/unmonitored) peptides may be the fastest-moving part of the longevity marketplace.

Some peptide-based medications have excellent evidence for specific medical conditions. For example, GLP-1–based therapies and related medications can produce substantial improvements in obesity and metabolic disease.

However no peptide stack is proven to slow human aging.

A 2026 review of therapeutic peptides in gerontology found that investigational compounds such as epitalon, GHK-Cu, BPC-157, TB-500, CJC-1295 and ipamorelin have promising biological rationales but limited clinical evidence and major gaps in long-term safety and validation (Mavrych et al., Frontiers in Aging, 2026).

And importantly, the commonly marketed peptide stacks do not have controlled human evidence demonstrating that they lower next-generation epigenetic aging clocks. Some, particularly those that boost NAD or IGF1 (growth hormone analogs), have potential for significant harm (i.e. risk of cancer potentiation) or accelerating aging (i.e. increasing IGF1).

The lesson isn’t “peptides are useless.” It is: we need more data to prove actual benefit for which patients, safe doses, and risks — and we need products that are safely monitored for purity, potency, and quality control. NEVER inject any product that says “For Research Purposes Only” or “Not for Human Use.”

What about NAD+, senolytics and “geroprotectors”?

This is another area where the laboratory science can sound more definitive than the human evidence. NAD+ biology, cellular senescence and pathways targeted by drugs such as rapamycin have produced compelling findings in cells and animals but also some serious safety concerns. Promising mechanisms do not always translate into meaningful benefits in people.

In a 2026 review of human studies using next-generation epigenetic clocks, nicotinamide riboside (an NAD+ precursor), senolytics, and rapamycin showed no detectable effect on these clocks (Johnson & Sinclair, Frontiers in Genetics, 2026).

That doesn’t prove these interventions can never work. It simply means the human evidence has not yet caught up with the enthusiasm.

A useful way to think about longevity treatments

Consider this simple framework to prioritize science, and your health, over marketing:

1. Does the treatment improve an outcome that matters to patients? Lowering an epigenetic clock is interesting. Preventing heart attacks, maintaining mobility, preserving cognition and extending healthy life are more important outcomes.
2. Has it been tested in randomized human trials in patients like me? Animal studies and laboratory experiments cannot tell us with confidence what will benefit an individual patient.
3. What are the risks and costs? An intervention should not be considered “low risk” simply because it is marketed as natural, regenerative or preventive.
4. What are we giving up by pursuing it? This may be the most overlooked question. The time and money spent on unproven therapies could instead go toward LIVING, and proven lifestyle interventions proven to work.

Inundated with information yet starving for wisdom

Longevity medicine is an exciting field. Aging biology is becoming increasingly measurable, and researchers are beginning to identify interventions that may genuinely influence biological aging.

But the science is not yet where the marketing often suggests it is.

We fail when we become so obsessed about health or longevity that we forget to live.

Right now, the strongest human evidence for slowing biological aging remains the lifestyle foundation: regular aerobic and resistance exercise, a healthy plant-rich dietary pattern, appropriate calorie intake, good sleep, and aggressive management of established cardiometabolic risk factors.

Meanwhile, many costly and time-consuming longevity-center offerings remain experimental. Some have interesting preliminary findings. Some have conflicting evidence. Others have little or no meaningful human evidence for the outcomes they are advertised to improve. (Johnson & Sinclair, Frontiers in Genetics, 2026)

Let’s not ignore the science, but let’s be honest about where the science ends and the sales pitch begins.

The best longevity intervention may not be the newest one. It may be the simple one you can actually sustain for decades.

Contact us to get started with a complimentary information session with LifeScape’s Director of Practice Development or call our office at 480.860.5500.

Selected references

• Johnson AA, Sinclair DA. Turning back time: a comprehensive list of interventions that decrease next-generation epigenetic aging clocks in humans. Frontiers in Genetics. 2026.
• Fiorito G, et al. DNA methylation-based biomarkers of aging were slowed down in a two-year diet and physical activity intervention trial: the DAMA study. Aging Cell. 2021.
• Borsky P, et al. Human clinical trial of plasmapheresis effects on biomarkers of aging. Scientific Reports. 2025.
• Fuentealba M, et al. Multi-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange. Aging Cell. 2025.
• Hachmo Y, et al. Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells. Aging. 2020.
• Autio I, et al. Diet Quality, Physical Activity, and Epigenetic Aging in the Finnish Working-Age Population. Journal of Nutrition. 2026.
• Mavrych V, et al. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Frontiers in Aging. 2026.

Patient note: Epigenetic clocks are research biomarkers, not definitive measures of an individual’s health or life expectancy. Treatment decisions should be based on established clinical indications, individual risks and benefits, and the best available evidence. The information within this article should not be considered medical advice.